Pharmaceuticals

Ranibizumab Market Developments And Opportunities Across 2026–2030

May 4, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Does The Market Size Of The Ranibizumab Market Compare Between 2026 And 2030?

The ranibizumab market size has shown consistent expansion in recent years. It is projected to increase from $2.76 billion in 2025 to $2.87 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 4.0%. This historical growth was driven by factors such as the increasing prevalence of age-related macular degeneration, the clinical validation of anti-VEGF therapy efficacy, a rising incidence of diabetic retinopathy, improved diagnostic imaging for retinal disorders, and early regulatory approvals for ranibizumab.

The ranibizumab market is projected to experience steady expansion in the coming years. It is forecast to reach $3.31 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 3.6%. This anticipated growth during the forecast period is primarily driven by factors such as the global rise in the aging population, increasing diabetes prevalence across the world, enhanced accessibility to advanced ophthalmic care, the growing adoption of intravitreal injections, and continuous enhancements in retinal disease screening programs. Significant trends expected in the forecast period include the increasing uptake of anti-VEGF therapies for retinal conditions, a developing preference for prefilled syringe formulations, a rising demand for treatments for diabetic eye disorders, the expansion of specialized ophthalmology care centers, and a greater utilization of long-term maintenance therapy for chronic retinal ailments.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16172&type=smp

Which Important Drivers Are Guiding The Ranibizumab Market Growth?

The ranibizumab market is anticipated to expand significantly due to the increasing occurrence of eye disorders. Eye conditions comprise various ailments that can negatively impact vision and overall eye health. The growing incidence of eye diseases is attributable to factors like aging populations and shifts in lifestyle, alongside an uptick in chronic illnesses such as diabetes. Ranibizumab is utilized in treating conditions like age-related macular degeneration and diabetic retinopathy, thereby helping to diminish vision impairment amid the rising prevalence of eye diseases. For example, in August 2023, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, stated that approximately 2.2 billion people globally experience either near or distance vision impairment. Hence, the increasing prevalence of eye diseases will propel the growth of the ranibizumab market.

How Is Segmentation Applied In The Ranibizumab Market Segment Analysis?

The ranibizumab market covered in this report is segmented –

1) By Product: Single Use Prefilled Syringe, Single Use Glass Vial

2) By Application: Wet Age Related Macular Degeneration (AMD), Diabetic Retinopathy (DR), Diabetic Macular Edema (DME), Myopic Choroidal Neovascularization (MCNV), Retinal Vein Occlusion (RVO)

3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Other Distribution Channels

Subsegments:

1) By Single Use Prefilled Syringe: 0.3 Ml Syringe, 0.5 Ml Syringe, 1 Ml Syringe, Other Volume Variants

2) By Single Use Glass Vial: 0.5 Mg Or 0.05 Ml Vial, 1.0 Mg Or 0.1 Ml Vial, 2.0 Mg Or 0.2 Ml Vial, Other Volume Variants

What Trends Are Influencing The Evolution Of The Ranibizumab Market?

Companies operating within the ranibizumab market are increasingly concentrating on cost-efficient therapies, such as ranibizumab biosimilars, to manage and avert vision impairment in individuals with retinal disorders. A ranibizumab biosimilar is a biological drug substantially similar to the original ranibizumab, yet it is marketed under a different brand name, offering a more budget-friendly alternative while upholding comparable effectiveness and safety. For instance, in April 2024, Formycon AG, a Germany-based biotechnology company, along with Bioeq AG, a Switzerland-based biopharmaceutical company, announced the commercial release of FYB201, a biosimilar to Lucentis (Ranibizumab), in Canada and Switzerland. This launch followed the marketing authorization granted by Health Canada under the brand name Ranopto and by Swissmedic under the brand name Ranivisio. FYB201 provides a new, high-quality, effective, and affordable treatment option for patients suffering from severe retinal diseases. It has already demonstrated its significance as a cost-effective treatment choice for patients in the USA and various parts of Europe.

Who Are The Companies Participating In The Ranibizumab Market Environment?

Major companies operating in the ranibizumab market are F. Hoffmann-La Roche AG, Genentech Inc., Bayer AG, Novartis AG, Biocon Limited, Samsung Biologics Co Ltd, Celltrion Healthcare Co Ltd, Formycon AG, Coherus BioSciences Inc, Xbrane Biopharma AB, Alvotech, Stada Arzneimittel AG, Sun Pharmaceutical Industries Ltd, Dr. Reddy’s Laboratories Ltd, Cipla Limited, Lupin Limited, Glenmark Pharmaceuticals Limited, Intas Pharmaceuticals Ltd, Enzene Biosciences Ltd, Amman Pharmaceutical Industries

Get The Full Ranibizumab Market Report:

https://www.thebusinessresearchcompany.com/report/ranibizumab-global-market-report

Which Region Accounts For The Largest Portion Of The Ranibizumab Market?

North America was the largest region in the ranibizumab market in 2025. The regions covered in the ranibizumab market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Ranibizumab Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/ranibizumab-global-market-report

Browse Through More Reports Similar to the Global Ranibizumab Market 2026, By The Business Research Company

Ranibizumab Market Report 2026

https://www.thebusinessresearchcompany.com/report/ranibizumab-global-market-report

Ibrutinib Market Report 2026

https://www.thebusinessresearchcompany.com/report/ibrutinib-global-market-report

Takaful Market Report 2026

https://www.thebusinessresearchcompany.com/report/takaful-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795